Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
GPRC5D CAR-T potentially demonstrates enhanced effectiveness relative to BCMA CAR-T in treating patients with RRMM. Therefore, GPRC5D CAR-T can be regarded as the preferred therapeutic option for RRMM, particularly among patients who have undergone relapse subsequent to BCMA CAR-T treatment.
Authors
- Bo Yang (ORCID: https://orcid.org/0000-0001-7529-2085)
- Yang Liu (ORCID: https://orcid.org/0000-0003-4874-4773)
- Guangyang Liu (ORCID: https://orcid.org/0000-0002-8474-7106)
- Sanbin Wang (ORCID: https://orcid.org/0000-0002-4802-0292)
- Feiqing Wang
- Juan Chen (ORCID: https://orcid.org/0000-0002-4077-2457)
- Xu Yang (ORCID: https://orcid.org/0000-0002-5752-7255)
- Dongxin Tang
- Jinyang Cheng
- Xu Xiao (ORCID: https://orcid.org/0000-0003-3743-3582)
- Yanju Li (ORCID: https://orcid.org/0000-0003-2924-4319)
- Zhixu He
- Xiaoshuang Yuan
Institutions
- Guiyang Medical University (CN)
- Tianjin University (CN)
- Guizhou University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-23
- DOI
- https://doi.org/10.3389/fimmu.2024.1466443
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guizhou Province